Conoa-B (02162) announced results for the year ended December 31, 2023. The group received revenue...
According to the Zhitong Finance App, Conoa-B (02162) announced the results for the year ended December 31, 2023. The group obtained revenue of RMB 354 million (same unit), an increase of 254% year on year; R&D expenses of 596 million yuan, up 18% year on year; loss of 318 million yuan during the adjusted year, up 25% year on year; parent company owners should account for a loss of 359 million yuan, an increase of 16.63% year on year; loss per share.
With the expertise of the company's clinical development team, the company can effectively design and carry out the company's clinical trials, and show the company's advantages in drug innovation through excellent clinical research and development results, while the company's clinical development team achieves this goal through carefully designed test plans and superb test operation technology. The team coordinates clinical development strategies and trial plans for the company's drug candidates, and manages trial implementation with the assistance of a reputable CRO in a low-cost and efficient manner. The company's medical and translational researchers identify and test biomarkers, guide patients to select and analyze clinical data to guide clinical research and pre-clinical evaluation. Since the company's clinical-stage drug candidates are in the top three of the domestic target drugs or drugs of the same class to obtain approval for clinical trials in China and/or the US, the company has attracted many first-level hospitals and top leading researchers (PIs) to join the company's clinical trials. The company believes that long-term cooperative relationships with such medical partners will be of great benefit to the company.
In order to ensure the production and supply of high-quality and affordable antibody drugs, the company has been working to strengthen internal production capacity. The company has developed high-expression cell lines in-house to ensure high antibody production yield and maintain low costs. By the end of the reporting period, the total production capacity of the production site in Chengdu had reached 18,600 liters, and all designs complied with the cGMP requirements of the State Drug Administration and FDA.